酪氨酸激酶抑制剂治疗慢性粒细胞白血病的研究进展
摘要
bcr—abl编码蛋白属非受体酪氨酸激酶，其二聚体形式活性失控，导致自身及细胞内许多底物蛋白的酪氨酸残基磷酸化，激活多条信号传递途径，诱导细胞恶性转化和增殖，抑制细胞凋亡等，从而导致慢性粒细胞白血病（CML）。由于认识到CML的发病与酪氨酸激酶活性有关，人们开始研制治疗CML的酪氨酸激酶抑制剂。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2009年第9期644-646,共3页
Chinese Journal of Hematology
参考文献20
-
1Jiang XY,Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J National Cancer Institute,2007,99:680-693.
-
2Nicolini FE, Hayette S, Corm S,et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a 33151 BCR-ABL mutation. Haematologica, 2007,92: 1238-1241.
-
3le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111: 1834-1839.
-
4Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res,2008, 68:9809-9816.
-
5Fabarius A, Giehl M, Rebacz B, et al. Centrosome aberrations and G1 phase arresl after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica, 2008, 93: 1145- 1154.
-
6Hoehhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia,2008, 22:1200-1206.
-
7Cardama AQ, Kantarjian H, Jones D, et al. Dasatinib (BMS- 354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 2007, 109:497-499.
-
8Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 2007,92:401-404.
-
9Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 2007, 110:40054-011.
-
10Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell ,2008,14:485-493.
-
1结肠肿瘤[J].国外科技资料目录（医药卫生）,2002(6):119-122.
-
2传良敏,黄文芳.肿瘤转移抑制基因及其作用机制[J].国外医学（临床生物化学与检验学分册）,2005,26(7):430-432.
-
3于超,魏莲枝.肿瘤细胞TRAIL信号传递途径中抗凋亡机制的研究进展[J].重庆医学,2006,35(7):655-658. 被引量：1
-
4马军.慢性粒细胞白血病伊马替尼耐药性的机制与对策[J].中华肿瘤防治杂志,2006,13(8):561-564. 被引量：3
-
5肿瘤形态学(组织病理类型)[J].国外科技资料目录（医药卫生）,2002(6):97-99.
-
6周晓霞,崔潇,付贺飞.FAK在恶性肿瘤中的作用的研究进展[J].中国实用医药,2009,4(17):259-260. 被引量：1
-
7王文静,王茂玉,王明玉.雌激素、Fak与乳腺癌关系的研究进展[J].实用癌症杂志,2008,23(1):102-104. 被引量：8
-
8陈玉英,梁后杰.黏着斑激酶在肿瘤发生中的作用研究进展[J].实用癌症杂志,2008,23(2):203-204. 被引量：4
-
92种基因的高表达预示乳腺癌患者生存率较低[J].基础医学与临床,2005,25(11):1027-1027.
-
10赵丽娟,张茹慧.STAT3、siRNA及口腔颌面部鳞状细胞癌的治疗[J].临床口腔医学杂志,2006,22(4):250-252. 被引量：5
